Status:
COMPLETED
Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control in T2DM
Lead Sponsor:
Norbert Hermanns
Collaborating Sponsors:
German Center for Diabetes Research
University of Giessen
Conditions:
Diabetes Mellitus, Type 2
Depressive Symptoms
Eligibility:
All Genders
18-70 years
Brief Summary
DIA-LINK2 is a prospective observational study analysing longitudinal associations and mediating links between diabetes distress (DD), depressive symptoms (DS) and glycaemic outcomes in people with ty...
Detailed Description
DIA-LINK2 is a prospective observational study analysing longitudinal associations between diabetes distress (DD), depressive symptoms (DS) and glycaemic outcomes in people with type 2 diabetes (T2DM)...
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- Diabetes duration at least 1 year
- Age between 18 and 70 years
- Sufficient German language skills
- Informed consent
- Smartphone available
Exclusion
- Capacity for consent lacking
- Illness with significant impairment of cognitive functioning (e.g. dementia)
- Severe somatic illness or mental disorder which interferes with study participation or might confound the results (dialysis-dependent renal failure; heart failure, i.e. New York Heart Association (NYHA) class III or IV; cancer requiring treatment; schizophrenia/psychotic disorder; bipolar disorder; severe eating disorder F50.0/F50.2; personality disorder)
- Terminal illness
- Being bedridden
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT04438018
Start Date
July 1 2020
End Date
March 31 2022
Last Update
April 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of the Diabetes Academy Mergentheim, Diabetes Center Mergentheim
Bad Mergentheim, Baden-Wurttemberg, Germany, 97980